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ABSTRACT 
Background: Duloxetine hydrochloride, a selective serotonin (5-HT) and 
norepinephrine (NE) reuptake inhibitor, is relatively balanced in its affinity for 
both 5-HT and NE reuptake inhibition and is the first US Food and Drug 
Administration-approved prescription drug for the management of diabetic pe- 
ripheral neuropathic pain (DPNP). 
Objectives: The aim of this study was to determine whether management of 
DPNP with duloxetine interferes with the treatment of diabetes. It also exam- 
ined the tolerability of long-term exposure to duloxetine with regard to the pro- 
gression of diabetic complications, and assessed the impact of DPNP manage- 
ment with duloxetine versus routine care. 
Methods: This was a 52-week, multicenter, e-randomized, open-label exten- 
sion of a parallel, double-blind, randomized, placebo-controlled, acute (12-week) 
study. Patients who completed the duloxetine or placebo acute treatment 
period were randomly reassigned in a 2:1 ratio to treatment with duloxetine 
60 mg BID or routine care for an additional 52 weeks. The study included male 
and female outpatients aged _>18 years with a diagnosis of DPNP caused by 
type 1 or type 2 diabetes. Over the course of the 52-week study, visits were sched- 
uled on the following weeks (of the extension phase of the study): 1 (via phone 
only), 2, 4, 8, 12, 20, 28, 40, and 52. Tolerability was assessed by review and 
analyses of discontinuation rates, adverse vents (AEs), laboratory data, vital 
signs, electrocardiographic results, concomitant medications, and diabetic 
complications. Treatment-emergent AEs (TEAEs) were defined as AEs that 
appeared uring therapy (were not present at baseline) or were exacerbated 
during treatment. Data on AEs and concomitant medications were collected at 
every visit. Data on blood pressure, heart rate, and significant hypoglycemic 
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events were collected atevery visit starting from week 2. Fasting clinical chem- 
istry and electrolyte group laboratory assessments were done at every visit, 
starting from week 4. Electrocardiographic data was collected at weeks 4 and 
52, and glycosylated hemoglobin and lipid profile data were collected at weeks 20 
and 52. Hematology and urinalysis laboratory assessments and diabetic ompli- 
cation assessments were done at week 52. All safety data was assessed in cases 
of early discontinuation. Treatment differences on quality of life (QOL) were 
compared using the Short Form-36 Health Status Survey (SF-36) and the EQ-5D 
instrument of the European Health-Related Quality of Life Measures. This was 
assessed at the last visit or at early discontinuation. 
Results: The open-label extension-phase study included 337 patients (dulox- 
etine, n = 222; routine care, n = 115). For the duloxetine group, mean age was 
60.2 years, 61.3% were male, and 78.4% were white. For the routine-care group, 
mean age was 58.9 years, 60.0% were male, and 74.8% were white. Mean weight 
was 95.3 kg for both groups. None of the TEAEs occurred significantly more 
often in the duloxetine-treated group than i  the routine-care-treated group. No 
TEAEs were reported by >10% of patients in the duloxetine group. The TEAEs 
reported by >10% of patients in the routine-care group included izziness 
(11.3%), somnolence (13.0%), headache (10.4%), and vomiting (10.4%). No sig- 
nificant differences were found between treatment groups in the occurrence 
of serious AEs or in the number of patients discontinuing because of AEs. 
Duloxetine was significantly better than routine care on the bodily pain sub- 
scale of the SF-36 (mean change: 1.5 vs -4.1; P = 0.021) and on the EQ-5D (mean 
change: -0.00 vs -0.09; P = 0.001). 
Conclusions: Over 52 weeks of follow-up, treatment ofthese diabetic patients 
with duloxetine for peripheral neuropathic pain was associated with outcomes 
similar to, or significantly better than, that of routine care on most measures of 
tolerability, diabetic complications, and QOL. (Curr Ther Res Clin Exp. 2006;67: 
283-304) Copyright © 2006 Excerpta Medica, Inc. 
Key words: duloxetine, diabetic peripheral neuropathic pain, antidepressant, 
pain, serotonin, norepinephrine. 
INTRODUCTION 
Diabetes affects -7% (20.8 million) of the population in the United States. 1
Diabetic peripheral neuropathic pain (DPNP) is a common complication of dia- 
betes that affects 10% to 20% of diabetes patients. 2,3 The pain has often been 
described as an "aching, burning, stabbing, or tingling" sensation. 4 Although 
the pathophysiology of diabetic neuropathy is not fully understood, suboptimal 
glycemic control appears to be a major contributor to diabetic neuropathy. 5 
This disease is difficult to treat, although it is possible to delay the progression 
of diabetic neuropathy by optimizing lycemic ontrol. 6
Several medications have been used for treating DPNP, including tricyclic 
antidepressants (eg, amitriptyline, 7 imipramine, 8 and desipramine9), certain anti- 
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convulsants (eg, gabapentinl°), and opioid analgesics (eg, tramadol, 11controlled- 
release oxycodonesl2). However, these drugs are often limited by their anti- 
cholinergic, c¢-adrenergic blocking, and central nervous ystem adverse vents 
(AEs). Recently published ata support he use of venlafaxine, pregabalin, and 
duloxetine in the acute treatment of DPNP. 13-15 
Other evidence suggests that endogenous inhibitory mechanisms of pain 
might be dysfunctional in pathologic pain states uch as DPNP. 16 Serotonin (5-HT) 
and norepinephrine (NE) have been implicated in mediating endogenous anal- 
gesic mechanisms via the descending inhibitory pain pathways in the brain and 
spinal cord. 17-20 
Duloxetine hydrochloride, a dual reuptake inhibitor of 5-HT and NE, was first 
approved in August 2004 by the US Food and Drug Administration for the treat- 
ment of major depressive disorder (MDD), and subsequently for treatment of 
DPNP in September 2004. 21 Duloxetine lacks significant affinity (K~) for muscarin- 
ic (K i = 3000 nM), histamine 1 (K i = 2300 nM), C¢l-adrenergic (K i = 8300 nM), 
c¢2-adrenergic (K i = 8600 nM), dopamine 2 (K i = 14000 nM), 5-HT1A (K i > 5000 nM), 
5-HT1B (K i [SD] = 3959 [810] nM), 5-HT1D (K i > 3000 nM), 5-HT2A (K i [SD] = 504 
[87] nM), 5-HT2c (K i [SD] = 916 [190] nM), and opioid receptors (K i > 1000 nM); 
it also has weak affinity for the dopamine transporter (K i [SD] = 240 [23] nM). 22 
The efficacy and tolerability of duloxetine in the short-term (12-week) man- 
agement of DPNP were reported in the acute phase of the present study. 15 In that 
double-blind, randomized, placebo-controlled trial, treatment with duloxetine 
was well tolerated and significantly different from placebo on the primary and 
nearly all secondary efficacy measures (including 24-hour average pain severity, 
24-hour worst pain score, night pain score, Brief Pain Inventory [BPI] average 
pain severity, BPI interference [average of 7 interference questions], BPI worst 
pain severity, BPI least pain severity, BPI severity pain right now, Clinical Global 
Impression of Severity, Patient's Global Impression of Improvement, and Short- 
Form McGill total score), including health-related outcomes. 15Patients treated 
with duloxetine 60 mg QD and 60 mg BID had significantly greater improvement 
compared with placebo n the 24-hour average pain score, beginning I week after 
randomization and continuing through the 12-week trial. Efficacy was similar for 
duloxetine 60 mg QD and 60 mg BID in this trial (on most outcome measures), but 
duloxetine 60 mg QD was associated with fewer discontinuations due to AEs 
(duloxetine 60 mg QD = 13.2%; duloxetine 60 mg BID = 19.5%). Given the observed 
efficacy and tolerability in the acute management of DPNP, the present open- 
label study phase was conducted to assess the tolerability and health outcomes 
of duloxetine versus routine care in the long-term management of DPNP. 
The aim of this study was to examine whether management of DPNP with 
duloxetine interferes with the treatment of diabetes. It also examined the toler- 
ability of up to 52 weeks of exposure to duloxetine with regard to the progres- 
sion of diabetic complications, and assessed the impact of DPNP management, 
with duloxetine versus routine care, on patient-reported outcomes associated 
with quality of life (QOL). 
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METHODS 
Study Design 
This 52-week, multicenter (23 study centers), randomized, open-label trial was 
an extension of a 12-week (acute phase) randomized, controlled, clinical trial con- 
sisting of patients with DPNP. In the acute phase of the study, 15 patients were an- 
domly assigned to treatment with duloxetine 20 mg QD, 60 mg QD, 60 mg BID, or 
placebo. After completion of the acute phase, patients were recruited to partici- 
pate in the extension phase and were randomly reassigned (2:1) to duloxetine 
60 mg BID or routine care. 
Study Cohort 
To be enrolled in the acute phase, patients were quired to experience pain 
due to bilateral peripheral neuropathy caused by type 1 or type 2 diabetes mel- 
litus and to be ~18 years of age. Pain had to initiate in the feet, with relatively 
symmetric onset. Daily pain must have been present for a minimum of 6 months. 
The diagnosis was confirmed by a score of ~3 on the physical examination por- 
tion of the Michigan Neuropathy Screening Instrument (MNSI). 23 The primary 
efficacy measure for the acute phase of the study was the reduction in weekly 
mean of the 24-hour mean pain severity scores (computed from diary scores 
between 2 site visits), as measured by an 11-point Likert scale (0 = no pain to 
10 = worst possible pain) completed aily by the patients in the diary. A 
reduction of -2 points or -30% in the pain-intensity numeric rating scale repre- 
sented a clinically important difference. 24
Patients were blinded to treatment in the acute phase. Other than receiving 
medications and medical care free of charge, patients were not compensated 
for participation i this trial. 
Patients were excluded from the acute phase of the study if, over the past year, 
they met criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IIO 25 for a diagnosis of Axis I depression, MDD, depression-partial 
remission, dysthymic disorder, generalized anxiety disorder, or alcohol or eating 
disorders as determined by response to the Mini International Neuropsychiatric 
Interview (MINI). Patients were also excluded if they reported, via the MINI, any 
current or past DSM-IVdiagnosis of mania, bipolar disorder, or psychosis. Patients 
were excluded if they had pain that might not be clearly differentiated from DPNP 
or conditions that interfered with the assessment of DPNP. 
The ethics committee at each site approved the entire study protocol in 
accordance with the principles of the Declaration of Helsinki. 26 Patients pro- 
vided written informed consent before participation n any study-related proce- 
dures. Patients' consent was obtained before the acute phase and covered the 
extension phase of the study. 
Treatments 
Patients were randomly assigned to open-label treatment and received either 
duloxetine 60 mg BID (escalated from 40 mg BID in 3 days) or routine care. The 
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routine-care group was treated with therapies that the investigator and the patient 
believed would provide optimal benefit or the patient. The duloxetine group was 
allowed all treatments offered to the routine-care group with the exception of anti- 
depressants, anticonvulsants, and antipsychotics. During the extension phase, pa- 
tients in both arms were permitted to use rescue analgesics including paraceta- 
mol, NSAIDs, or opioid analgesics. Over the course of the 52-week study, visits were 
scheduled on the following weeks: 1 (via phone only), 2, 4, 8, 12, 20, 28, 40, and 52. 
General Safety 
Tolerability measures recorded at every office visit included spontaneously 
reported AEs, concomitant medications, vital signs, and the occurrence of sig- 
nificant hypoglycemic events. Patients were queried at every office visit about 
significant hypoglycemic events with the use of a specific questionnaire. A sig- 
nificant hypoglycemic event was any episode that required intervention with 
glucose, glucagon, food, drink, or assistance. Solicited hypoglycemic events were 
not entered as AEs, but were analyzed and reported separately. Data on AEs and 
concomitant medications were collected at every visit. Data on blood pressure, 
heart rate, and significant hypoglycemic events were collected at every visit start- 
ing from week 2. Fasting clinical chemistry and electrolyte group laboratory 
assessments were done at every visit, starting from week 4. Electrocardiographic 
data was collected at weeks 4 and 52, glycosylated hemoglobin (HbAlc and lipid 
profile data were collected at weeks 20 and 52. Hematology and urinalysis labora- 
tory assessments and diabetic complication assessments were done at week 52. 
All safety data was assessed in cases of early discontinuation. Mean change and 
the percentage of abnormal results were considered, and the magnitude of these 
mean changes was not considered to be of clinical significance. 
Diabetic Complications 
Diabetic complications were measured using the physical examination por- 
tion of the MNS123 (neuropathy progression), microalbumin/creatinine ratio 
(nephropathy progression, defined as a significant change [P < 0.05] in the 
microalbumin/creatinine ratio from baseline to end point), and ophthalmologic 
examination with fundus photographs (ret inopathy progression). Diabetic com- 
plication assessments were done at week 52. The ophthalmologic examination 
assessed 4 categories of events: worsening of visual acuity, need for surgical 
procedures,  panretinal photocoagulation, or vitrectomy. If the patient required 
macular laser surgery, panretinal photocoagulation, or vitrectomy, the retinopa- 
thy was judged as having progressed. If the patient did not require surgery dur- 
ing the trial, changes from baseline in 3-field fundus photographs were rated in 
terms of severity by an ophthalmologist masked to the treatment. 
Vital Signs 
Sitting heart rate and blood pressure were recorded at every office visit. A pa- 
tient was considered to have a sustained elevation in blood pressure after random- 
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ization if he or she met he following criteria: sitting diastolic blood pressure 
_>85 mm Hg and an increase from baseline of 10 mm Hg for 3 consecutive visits, 
or sitting systolic blood pressure _>130 mm Hg and an increase from baseline of 
10 mm Hg for 3 consecutive visits. 
Health Outcomes 
The impact of treatment on patient-reported QOL was assessed using the 
Short Form-36 Health Status Survey (SF-36) 27 and the EQ-5D instrument of the 
European Health-Related Quality of Life Measures. 28 The SF-36 is a generic 
instrument for rating patients' self-perceived health-related QOL 27'29 and assesses 
both the physical and mental dimensions of QOL. The SF-36 questionnaire is a 
standardized health-status profile that measures 8 categories of health, 3° in- 
cluding physical functioning, limitations in usual role activities due to physical 
health problems (physical role limit), bodily pain, general health perceptions, 
vitality, social functions, limitations in usual role activities due to emotional 
problems (emotional role limit), and mental health. The replies to individual 
items in each domain were added to derive a score, which was converted, using 
an algorithm, to a scale from 0 (poor health) to 100 (good health). 
The EQ-5D self-report questionnaire is a standardized instrument used as a 
measure of health-related QOL. 28 Health status is defined in terms of 5 dimensions: 
mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. 
Each dimension includes 3 possible levels of response (1 = "no problems," 2 = 
"some/moderate problems," or 3 = "extreme problems"). Respondents are asked 
to choose 1 level that reflects their "own health state today" for each of the 
5 dimensions. An overall index measuring QOL is derived from the response to 
the 5 dimensions. 
Statistical Analysis 
All analyses were conducted on an intent-to-treat basis. All randomized patients 
who entered the extension phase were included in the tolerability analyses. 
For measurements of diabetic complications, baseline was defined as the last 
value of the screening period before the acute phase of the trial. Changes from 
baseline in these measures were assessed using a fixed-effect analysis of vari- 
ance (ANOVA) model with terms for acute treatment, extension treatment, and 
interaction between acute treatment and extension treatment. Categoric vari- 
ables were analyzed using the Cochran-Mantel-Haenszel g neral association 
test, 31 stratified for the treatment received in the acute phase. 
For all other measurements,  baseline was defined as the last available value 
of the acute phase. Changes from baseline in continuous measures were assessed 
using a fixed-effect analysis of covariance model with terms for treatment, 
investigator, and baseline values. Categoric variables were analyzed using the 
Fisher exact test. Treatment-group differences in laboratory analytes (except 
fasting glucose) were assessed using an ANOVA model on the rank-transformed 
data with terms for treatment and investigator. 
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For all analyses, treatment effects were tested at a 2-sided significance l vel 
of 0.05. If the treatment-by-investigator in e action term was significant (P ~ 0.10), 
the interaction term was left in the model. Throughout this manuscript, he 
term significant indicates tatistical significance (P < 0.05), and mean change 
refers to the least squares mean change. The least squares means presented in
the manuscript are the expected treatment-group means when the outcome of 
interest is adjusted for the association between the outcome of interest and the 
dependent variables included in the ANOVA model. 32 
Statistical analysis was conducted using SAS software, version 8.0 (SAS Insti- 
tute Inc., Cary, North Carolina). 
RESULTS 
Baseline Characteristics 
Three hundred thirty-seven (73.7%) of the 457 patients who were enrolled in 
the acute phase were also enrolled in the open-label, extension-phase of the 
study. The duloxetine group consisted of 222 patients, and the routine-care 
group included the remaining 115 patients (Figure). The demographic charac- 
teristics and baseline assessments for both treatment groups are presented in 
Table I. The majority of patients in both treatment groups had type 2 diabetes 
(88.4%, overall). No significant treatment-group differences were observed in 
baseline characteristics. 
Treatment  by Phase 
Of the 222 patients assigned to receive duloxetine in the extension phase, 165 
(74.3%) patients received uloxetine treatment in the acute phase of the study 
(duloxetine [acute]/duloxetine [extension]), and 57 (25.7%) patients received 
placebo treatment in the acute phase (placebo [acute]/duloxetine [extension]). 
Of the 115 patients assigned to receive routine care in the extension phase of 
the study, 87 (75.7%) patients received uloxetine treatment in the acute phase 
of the study (duloxetine [acute]/routine care [extension]), and 28 (24.3%) pa- 
tients received placebo treatment in the acute phase (placebo [acute]/routine 
care [extension]). 
Medicat ion Use 
Table II summarizes the concomitant medications used by patients in the 
duloxetine and routine-care groups. Medications were categorized into thera- 
peutic categories which best described their indication for use. If many patients 
used a particular class (ie, statins for cholesterol lowering), then all drugs in 
that class were included under that category (in this case, statins). Drugs used 
to lower other lipids (eg, triglycerides) were included under the lipid lowering 
catagory. Patients in the routine-care group used gabapentin (47.8% [55/115]), 
venlafaxine (22.6% [26/115]), amitriptyline (22.6% [26/115]), and alpha-lipoic acid 
(10.4% [12/115]) most frequently for pain associated with diabetic neuropathy. 
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Patients randomized 
(N = 337) 
I 
Duloxetine 60 mg BID 
(n = 222) 
Routine care 
(n = 115) 
Discontinued 
(n = 63) 
Reason: 
• Adverse  event (31) 
• Lack of efficacy (4) 
• Lost to fol low-up (4) 
• Personal conflict or 
other patient decision (18) 
• Sponsor's decision (1) 
• Protocol violation (1) 
• Death (2) 
• Physician's decision (2) 
Discontinued 
(n = 22) 
Reason: 
• Adverse event (11) 
• Lack of efficacy (1) 
• Lost to fol low-up (3) 
• Personal conflict or 
other patient decision (4) 
• Sponsor's decision (1) 
• Protocol violation (0) 
• Death (0) 
• Physician's decision (2) 
Protocol completed 
(n = 159) 
Protocol completed 
(n = 93) 
Figure. Flow chart representing study completion and reasons for  discontinuation in 
study patients wi th  diabetic peripheral neuropathic pain (N = 337) randomized 
(2:1) into 2 treatment groups. 
The concomitant medications used by _>50% of patients in the duloxetine-treated 
group were oral hypoglycemics (75.2% [167/222]), NSAIDs (64.4% [143/222]), 
and antihypertensive agents (63.5% [141/222]). Concomitant medications used 
by _>50% of patients in the routine-care group were oral hypoglycemics (76.5% 
[88/115]), NSAIDs (68.7% [79/115]), antihypertensive agents (63.5% [73/115]), 
and diet supplements (55.7% [64/115]). 
Safety Profile 
Reasons for Discontinuation 
Sixty-three (28.4%) of 222 duloxetine-treated patients and 22 (19.1%) of 115 
routine-care-treated patients discontinued treatment. No significant difference 
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Table I. Demographic characteristics and baseline assessments for study patients 
with diabetic peripheral neuropathic pain (N -- 337). 
Duloxetine Routine Care 
Variable (n = 222) (n = 115) 
Age, mean (SD), y 60.2 (1 0.7) 58.9 (11.3) 
Sex, no. (°4) 
Male 136 (61.3) 69 (60.0) 
Female 86 (38.7) 46 (40.0) 
Race or origin, no. (04)* 
White 174 (78.4) 86 (74.8) 
Hispanic 24 (1 0.8) 1 3 (11.3) 
Black 1 6 (7.2) 1 2 (10.4) 
East/Southeast Asian 3 (1.4) 2 (1.7) 
Western Asian 4 (1.8) 0 
Other 1 (0.5) 2 (1.7) 
Height, mean (SD), cm 1 71.0 (11.1 )t 1 72.3 (10.3) 
Weight, mean (SD), kg 95.2 (19.9) 95.4 (23.6) 
Type of diabetes mellitus, no. (%) 
Type 1 26 (I 1.7) 13 (I 1.3) 
Type 2 196 (88.3) 102 (88.7) 
Duration of diabetes, mean (SD), y 12.1 (10.3) 10.6 (8.7) 
Duration of diabetic neuropathy, mean (SD), y 3.8 (3.8) 3.5 (4.0) 
MNSI score, mean (SD) 5.1 (1.5) 5.4 (1.5) 
24-Hour average pain score,$ mean (SD) 5.9 (1.6) 5.9 (1.6) 
MNSI = Michigan Neuropathy Screening Instrument] 9
*Totals may not add to 100% due to rounding. 
tn = 221. 
~Measured by an 11 -point Likert scale (0 = no pain to 10 = worst possible pain). 
was found in overall rates of discontinuation. The total numbers of patients dis- 
continuing by week of treatment during the extension phase of the study (based 
on treatment in the acute phase) are shown in Table III. Rates of discontinua- 
tion due to AEs were not significantly different between the duloxetine (14.0% 
[31/222]) and routine-care (9.6% [11/115]) groups. No significant differences 
were found between treatment groups with regard to any single reason for dis- 
continuation. The most frequently reported AEs associated with discontinua- 
tion for both treatment groups together were myocardial infarction (duloxetine, 
0.9% [2/222]; routine care, 2.6% [3/115]) and hypertension (duloxetine, 0.9% 
[2/222]; routine care, 0.9% [1/115]). 
Adverse Events 
Of the 337 enrolled patients, 296 (87.8%) reported >1 treatment-emergent AEs 
(TEAEs). Significantly more events of vomiting (duloxetine, 3.2%; routine care, 10.4%; 
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Table II. Concomitant medications used by >5% of patients in either group with dia- 
betic peripheral neuropathic pain randomly assigned to treatment with 
duloxetine 60 mg BID or routine care for 52 weeks. Values are expressed as 
no. (%). 
Duloxetine Routine Care 
Drug Type (n = 222) (n = 115) 
Oral hypoglycemic 167 (75.2) 88 (76.5) 
NSAID 143 (64.4) 79 (68.7) 
Antihypertensive 141 (63.5) 73 (63.5) 
Insulin 99 (44.6) 47 (40.9) 
Diet supplement 97 (43.7) 64 (55.7) 
Statin 83 (37.4) 48 (41.7) 
Antibiotic 71 (32.0) 48 (41.7) 
Diuretic 62 (27.9) 46 (40.0) 
Gastrointestinal 44 (19.8) 29 (25.2) 
Topical, other 39 (1 7.6) 13 (11.3) 
Antihistamine 33 (14.9) 16 (13.9) 
Other 32 (14.4) 23 (20.0) 
Lipid-lowering 26 (11.7) 12 (10.4) 
Sex steroid 26 (11.7) 13 (11.3) 
Cardiac 24 (10.8) 14 (12.2) 
Steroid 24 (10.8) 14 (12.2) 
Hormone, other 21 (9.5) 6 (5.2) 
Antiplatelet 18 (8.1) 7 (6.1) 
Opiate 18 (8.1) 14 (2.2) 
Muscle relaxant 1 7 (7.7) 3 (2.6) 
Analgesic, topical 15 (6.8) 4 (3.5) 
Genitourinary 10 (4.5) 9 (7.8) 
Anticoagulant 9 (4.1) 13 (11.3) 
Decongestant 7 (3.2) 7 (6.1) 
Bronchodilator 7 (3.2) 6 (5.2) 
Expectorant 6 (2.7) 11 (9.6) 
Antidiarrheal 4 (1.8) 7 (6.1) 
SSRI 3 (1.4) 8 (7.0) 
Tricyclic antidepressant 1 (0.5) 41 (35.7) 
Gabapentin 0 55 (47.8) 
SNRI, other 0 43 (37.4) 
SSRI = selective serotonin reuptake inhibitor; SNRI = serotonin-norepinephrine reuptake inhibitor. 
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P = 0.011), pain in foot (duloxetine, 0.9%; routine care, 5.2%; P = 0.021), nail fungal 
infection (duloxetine, 0.5%; routine care, 3.5%; P = 0.048), hyperglycemia (duloxe- 
tine, 0%; routine care, 3.5%; P = 0.013), cataract extraction (duloxetine, 0%; routine 
care, 2.6%; P = 0.039), conjunctivitis (duloxetine, 0%; routine care, 2.6%; P = 0.039), dia- 
betic retinopathy (duloxetine, 0%; routine care, 2.6%; P = 0.039), and sinus congestion 
(duloxetine, 0%; routine care, 2.6%; P = 0.039) occurred in the routine-care-treated 
group than in the duloxetine-treated group. There were no events that the dulox- 
etine patients had statistically significantly more of compared with the routine- 
care patients. Overall, proportionally more routine-care patients experienced TEAEs 
compared with duloxetine patients (92.2% vs 85.6%) (P = NS). In the duloxetine 
group there was no TEAE that was reported by _>10% patients. TEAEs reported by 
_>5% of patients in this group were dizziness (9.0% [20/222]), fatigue (9.0% [20/222]), 
headache (7.7% [ 17/222]), nausea (7.7% [ 17/222]), somnolence (6.8% [ 15/222]), in- 
creased sweating (5.9% [13/222]), upper respiratory tract infection (5.4% 
[12/222]), constipation (5.4% [12/222]), hypertension (5.4% [12/222]), dry mouth 
(5.4% [12/222]), falls (5.4% [12/222]), back pain (5.0% [11/222]), diarrhea (5.0% 
[ 11/222]), and arthralgia (5.0% [ 11/222]). TEAEs reported by _>10% of patients in the 
routine-care group were somnolence (13.0% [ 15/115]), dizziness (11.3% [ 13/115]), 
headache (10.4% [12/115]), and vomiting (10.4% [12/115]). TEAEs reported by 
_>5% of patients in the routine-care group were fatigue (9.6% [11/115]), nausea 
(9.6% [ 11/115]), upper respiratory tract infection (9.6% [ 11/115]), arthralgia (8.7% 
[10/115]), hypertension (7.0% [8/115]), nasopharyngitis (7.0% [8/115]), chest 
pain (7.0% [8/115]), pain in the limb (6.1% [7/115]), urinary tract infection 
(6.1% [7/115]), influenza (6.1% [7/115]), dry mouth (5.2% [6/115]), back pain 
(5.2% [6/115]), diarrhea (5.2% [6/115]), muscle cramp (5.2% [6/115]), skin ulcer 
(5.2% [6/115]), cellulitis (5.2% [6/115]), and pain in the foot (5.2% [6/115]). 
TEAEs were also reported based on the patients' previous treatment in the 
acute phase of the study. TEAEs reported by >10% of patients in the duloxetine 
(acute)/routine-care (extension) group were somnolence (14.9% [13/87]); dizzi- 
ness (12.6% [11/87]); headache, pain in extremity, and vomiting (11.5% [10/87], 
for each event); and peripheral edema (10.3% [9/87]). In the placebo (acute)/ 
duloxetine (extension) group, TEAEs reported by >10% of patients were somno- 
lence (17.5% [10/57]); nausea and dizziness (14.0% [8/57], for each event); 
fatigue and hyperhidrosis (12.3% [7/57], for each event); and influenza, erectile 
dysfunction, and back pain (10.5% [6/57], for each event). In the placebo 
(acute)/routine-care (extension) group, TEAEs reported by >10% of patients 
were fatigue (17.9% [5/28]); upper respiratory tract infection, hypertension, and 
dry mouth (14.3% [4/28], for each event); and nausea, pain in extremity, naso- 
pharyngitis, back pain, arthralgia, and skin ulcer (10.7% [3/28], for each event). 
There was no TEAE that was reported by >10% of patients in the duloxetine 
(acute)/duloxetine (extension) group (N = 165). 
During the study, 54 (16.0%) of 337 patients experienced serious AEs, 
which were defined as any study-related AE resulting in one of the following 
outcomes (or was significant for any other reason): death, initial or prolonged 
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inpatient hospitalization, a life-threatening experience, severe or permanent 
disability, or congenital anomaly. Serious AEs occurring in >1% of patients 
in either group included myocardial infarction (duloxetine, 2.7% [6/222]; rou- 
tine care, 4.3% [5/115]), cellulitis (duloxetine, 1.4% [3/222]; routine care, 
1.7% [2/115]), cerebrovascular ccident and chest pain (routine care, 1.7% 
[2/115], for each event), pneumonia (routine care, 1.7% [2/115]), and acute 
renal failure (routine care, 1.7% [2/115]). No significant treatment-group differ- 
ences were found in the occurrence of any serious AE. Two deaths were 
reported in the duloxetine treatment group: 1 patient with severe sepsis and 
1 patient after myocardial infarction. The principal investigator and sponsor 
considered both deaths to be unrelated to the study medication. 
Hypoglycemic Events 
The number of patients who had _>1 significant hypoglycemic episode be- 
tween 2 visits (those requiring intervention with glucose, glucagon, food, 
drink, or assistance) did not differ significantly between treatment groups 
(week 1: no episode; week 2: duloxetine, 9.3% [20/216] vs routine care, 
9.6% [11/115]; week 4: duloxetine, 9.4% [20/212] vs routine care, 10.7% [12/112]; 
week 8: duloxetine, 16.3% [34/208] vs routine care, 13.0% [14/108]; week 12: 
duloxetine, 12.8% [25/196] vs routine care, 15.4% [16/104]; week 20: duloxetine, 
19.1% [36/188] vs routine care, 17.5% [18/103]; week 28: duloxetine, 16.3% [29/178] 
vs routine care, 19.4% [19/98]; week 40: duloxetine, 13.5% [23/170] vs routine 
care, 25.8% [25/97]; and week 52: duloxetine, 16.5% [27/164] vs routine care, 
15.1% [14/93]). Significantly fewer duloxetine-treated patients (13.5% [23/170]) 
than routine-care-treated patients (25.8% [25/97]) had experienced hypoglycemic 
episodes by week 40 of the extension phase (P = 0.020). 
Laboratory Data 
Mean changes from baseline to end point in several chemistry analytes dif- 
fered significantly between treatment groups (Table IV). In order to have data 
included in the analyses of laboratory data, patients had to have results at both 
baseline and end point. Some patients had missing values at baseline, end point, 
or both, and were thus not included in the analyses. The duloxetine group had a 
significant increase in fasting glucose and a significant decrease in sodium com- 
pared with the routine-care-treated group (P = 0.021 and P = 0.001, respectively). 
The routine-care group had significant increases in creatinine and chloride (P = 0.025 
and P < 0.001, respectively), and significant decreases in aspartate aminotrans- 
ferase, alanine aminotransferase, and total cholesterol (P = 0.019, P = 0.026, and 
P = 0.002, respectively) compared with the duloxetine group. 
With the exception of low-density lipoprotein cholesterol (LDL-C), no signifi- 
cant differences were observed between treatment groups at end point in HbAlc 
or lipid-profile changes (Table V). Although both treatment groups had mean 
decreases in LDL-C, the mean change was significantly smaller for the duloxe- 
tine group than for the routine-care group (P = 0.001). 
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Table IV. Laboratory values: changes from baseline to end point for patients with 
diabetic peripheral neuropathic pain treated with duloxetine 60 mg BID or 
routine care (N = 332). Values are expressed as mean (SD). 
Duloxetine Routine Care 
Parameter (n = 218) (n = 114) P* 
Albumin, g/L -0.4 (2.7) -0.2 (3.0) 0.532 
Alkaline phosphatase, U/L 5.2 (21.9) 2.2 (18.3) 0.254 
ALT/SGPT, U/L 0.3 (11.0) -1.8 (8.9) 0.026 
AST/SGOT, U/L 0.2 (7.0) -2.2 (10.2) 0.019 
Bicarbonate, HCO3, mmol/L -0.03 (2.5) -0.1 (2.7) 0.601 
Bilirubin, total, tJmol/L -0.3 (3.5) -0.4 (3.3) 0.342 
Calcium, mmol/L 0.02 (0.1) 0.01 (0.1) 0.614 
Chloride, mmol/L 1.2 (3.3) 3.0 (4.0) <0.001 
Cholesterol, total, mmol/L 0.002 (1.0) -0.4 (1.2) 0.002 
Creatine phosphokinase, U/L 2.8 (68.8) 14.0 (199.3) 0.567 
Creatinine, tJmol/L 2.6 (11.5) 6.3 (14.6) 0.025 
GGT, U/L -0.2 (19.1) -5.1 (27.2) 0.545 
Glucose, fasting, mmol/L 1.0 (4.7) -0.6 (5.0) 0.021 
Inorganic phosphorus, mmol/L 0.04 (0.2) 0.01 (0.2) 0.332 
Potassium, mmol/L -0.02 (0.4) 0.00 (0.4) 0.504 
Protein, total, g/L 0.0 (4.2) -0.3 (4.0) 0.673 
Sodium, mmol/L -0.7 (2.7) 0.4 (3.5) 0.001 
Urea nitrogen, mmol/L 0.3 (1.8) 0.7 (1.9) 0.345 
Uric acid, tJmol/L -5.3 (61.7) 10.8 (61.9) 0.051 
ALT/SGPT = alanine aminotransferase/serum glutamate pyruvate transaminase; AST/SG©T = aspartate 
aminotransferase/serum glutamate oxaloacetate transaminase; GGT = gamma-glutamyl transferase. 
*P values determined using ananalysis of variance model on the rank-transformed data with terms for 
treatment and investigator. 
Diabetic Complications 
Michigan Neuropathy Screening Instrument 
No significant reatment-group differences were observed in the mean 
changes in the MNSI score from baseline (last value prior to acute phase) to end 
point (difference,-0.20 [95% CI,-0.57 to 0.16]). 
Retinopathy Progression 
No significant treatment-group differences were found in the proportion of 
patients with worsening of visual acuity (right eye: duloxetine, 5.7% [9/158] vs 
routine care, 7.4% [6/81]; left eye: duloxetine, 4.4% [7/158] vs routine care, 2.4% 
[2/82]). No significant reatment-group differences were noted in changes in 
retinopathy (right eye: duloxetine, 11.0% [11/99] vs routine care, 6.5% [3/46]; 
left eye: duloxetine, 10.0% [10/100] vs routine care, 8.7% [4/46]). No significant 
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treatment-group differences were found for required ophthalmologic surgical 
procedures,  reasons for panretinal photocoagulation, or reasons for vitrectomy. 
Microalbumin/Creatinine Ratio 
No significant treatment-group difference was observed in the change in 
microalbumin/creatinine ratio (mean change [SE]: duloxetine, 0.04 [0.03] vs rou- 
tine care, 0.08 [0.04]). 
Vital Signs and Electrocardiographic Results 
The difference in the mean change in sitting heart rate at end point was sig- 
nificant between the groups (Table ¥I). Twenty-one (9.6%) of 219 duloxetine- 
treated patients and 12 (10.4%) of 115 routine-care-treated patients had an 
increase in heart rate of <5 bpm from baseline, which is unlikely to be of clini- 
cal significance. Forty-one (18.7%) duloxetine patients and 27 (23.5%) routine- 
care patients had an increase in heart rate of _>5 bpm but <10 bpm; 119 (54.3%) 
duloxetine-treated patients and 50 (43.5%) routine-care patients had an in- 
crease in heart rate of _>10 bpm. These changes could be clinically meaningful 
in some patients, and the frequency of such changes is slightly higher in the 
duloxetine-treated group. Weight and blood pressure changes were not signifi- 
cantly different between the duloxetine and routine-care groups. 
One case (0.5%) of sustained blood pressure levation occurred in the duloxe- 
tine group and none in the routine-care group. There were statistically signifi- 
cant mean decreases in QT and PR for duloxetine-treated patients compared 
with routine-care-treated patients. No significant differences were noted between 
treatment groups in mean changes in corrected QT intervals using either the 
Fridericia or Bazett correction. 
Health Outcomes 
Compared with the routine-care group, patients in the duloxetine group had 
a significantly greater increase from baseline on the SF-36 bodily pain subscale 
score (P = 0.021). On the EQ-5D, the duloxetine group had a significantly smaller 
decrease from baseline than the routine-care group, and a significant reatment- 
by-investigator interaction was found (P = 0.001 and P = 0.003, respectively). 
Mean changes on the SF-36 and EQ-5D are summarized in Table ¥II. 
DISCUSSION 
In this 52-week, multicenter, open-label study of the management of DPNP, dulox- 
etine appeared to be as well tolerated as routine care in the population studied. 
No significant between-group differences were found in the reasons for discontin- 
uing treatment or the occurrence of serious AEs. However, some AEs were signif- 
icantly more frequent in the routine-care group than in the duloxetine group. 
Laboratory data analyses revealed some significant differences between 
duloxetine treatment and routine care treatment. Although statistically signifi- 
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cant, the mean changes were small, and none of these differences were deter- 
mined to be clinically meaningful based on the judgment of the investigators. 
No patients discontinued treatment because of these changes. The observation 
that duloxetine increased fasting glucose slightly suggests a possible effect on 
glycemic ontrol. No statistically significant difference was observed for HbAlc, 
but this finding would need verification in subsequent s udies before a conclu- 
sion about an effect on this parameter might be reached. The duloxetine and 
routine-care groups did not differ with respect o progression of neuropathy, 
nephropathy, or retinopathy. 
The differences observed in patient LDL-C levels have potential clinical 
significance. Because these differences were small, it is important not to draw 
conclusions from 1 study. Effects on lipids are being considered by examination 
of a pool of 3 studies, the results of which will be published separately. Con- 
clusions about the effects of duloxetine on lipids are deferred until that analy- 
sis has been completed. 
The treatment groups did not differ significantly with regard to mean 
changes in weight, blood pressure, or corrected QT interval. A significant differ- 
ence was found in the mean changes in heart rate: a 1.93 bpm increase was 
observed in the duloxetine group and a 1.78 bpm decrease was observed in the 
routine-care group, which was not considered to be clinically significant. 
As measured by the SF-36, patients treated with duloxetine reported signifi- 
cantly better health status with regard to bodily pain compared with patients 
treated with routine care. As demonstrated by the EQ-5D, duloxetine-treated 
patients reported significantly smaller negative impact on their QOL compared 
with routine-care-treated patients. Within the health-outcome measurements 
analyzed, the 8 subscales of the SF-36, and the physical and mental component 
summaries did not suggest a treatment-by-investigator interaction. The detec- 
tion of a treatment-by-investigator interaction in the EQ-5D might be spurious 
and is not likely to affect he overall results or conclusions. 
Study Limitations 
The primary objective of the present study was to determine the effects of 
long-term treatment of DPNP with duloxetine as compared with other options 
in a "real-world" clinical setting. As such, the comparison of treatment groups 
during the extension phase was secondary in purpose. Once patients were ran- 
domized to the duloxetine or routine-care group, treatment in the latter group 
was guided by the investigator's usual clinical practice and was not mandated 
by the protocol. It is reasonable to expect hat the heterogeneity among ap- 
proaches to the standard of care and the lack of blinding of physicians with 
regard to patients' treatment groups would introduce bias into the comparisons 
between treatment groups. As such, the direct comparison of duloxetine to 
other therapies hould be approached with caution. 
Other limitations apply to this study. First, it is reasonable to expect hat 
patients entering the extension phase would continue deriving benefit because 
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they had a positive experience in the acute study. However, the objective of this 
extension study was to assess long-term treatment. Second, because this study 
primarily assessed the safety profile, the only duloxetine dose used was 60 mg 
BID, and not the recommended starting dose of 60 mg QD. Third, the study was 
not designed or powered to quantify individual safety parameters or statisti- 
cally significant differences between AE reporting rates. 
CONCLUSIONS 
Over 52 weeks of open-label follow-up, treatment ofthese diabetic patients with 
duloxetine for peripheral neuropathic pain was associated with outcomes im- 
ilar to, or significantly better than, that of routine care on most measures of tol- 
erability, diabetic omplications, and QOL. 
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